A clinical study found that in 120 patients receiving neoadjuvant therapy for HER2-positive breast cancer with anthracyclines, taxanes, and CTX (as well as trastuzumab), the use of antibiotics after the start of treatment was associated with a poorer response rate and disease-free survival, possibly by affecting the dysbiosis of the intestinal microbiota and thereby influencing the effectiveness of neoadjuvant therapy [175]. The gene discussed is ERBB2; the disease is breast cancer.